Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23278770 | 0.87 | NOD2 (0.47) | NOD2SIRT5PTPN1NOD1ERAP2 | |
| SCHEMBL17951006 | 0.87 | SIRT5 (0.60) | NOD2SIRT5PTPN1NOD1GNPAT | |
| SCHEMBL27549889 | 0.87 | FOLH1 (0.56) | GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL10728112 | 0.87 | FOLH1 (0.56) | GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL30496630 | 0.86 | NOD2 (0.44) | NOD2SIRT5PTPN1NOD1ERAP2 | |
| SCHEMBL28971660 | 0.86 | NOD2 (0.44) | NOD2SIRT5PTPN1NOD1GNPAT | |
| SCHEMBL6840688 | 0.86 | SIRT5 (0.51) | SIRT5GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL6840416 | 0.86 | SIRT5 (0.51) | SIRT5GNPATFOLH1NAALAD2RIMKLA | |
| SCHEMBL10888261 | 0.86 | NOD1 (0.54) | NOD2SIRT5PTPN1NOD1ERAP2 | |
| SCHEMBL8582064 | 0.85 | NOD1 (0.44) | NOD2SIRT5PTPN1NOD1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4125603-A | PROTEIN | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1978-11-14 | — | — | US | claimed |
| US-12383609-B2 | Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to | INSTITUTE FOR RESEARCH IN BIOMEDICINE (CH) | 2025-08-12 | — | — | US | disclosed |
| US-20250186580-A1 | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN | TRIDEM BIOSCIENCE GMBH & CO KG (AT) | 2025-06-12 | — | — | US | disclosed |
| US-20250186595-A1 | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN | TRIDEM BIOSCIENCE GMBH & CO KG (AT) | 2025-06-12 | — | — | US | disclosed |
| US-20250059256-A1 | HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2025-02-20 | — | — | US | disclosed |
| EP-4486387-A1 | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A SS-GLUCAN OR A MANNAN | Tridem Bioscience GmbH & Co KG (AT) | 2025-01-08 | — | — | EP | disclosed |
| CN-119136838-A | Consisting of or comprising at least one beta-glucan or mannan conjugates of at least one beta-glucan or mannan | 特瑞德姆生物科技有限责任两合公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118909082-A | An isolated peptide | 俄亥俄州创新基金会 | 2024-11-08 | — | — | CN | disclosed |
| CN-110636855-B | Human PD1 peptide vaccine and use thereof | 俄亥俄州创新基金会 | 2024-08-09 | — | — | CN | disclosed |
| US-12048738-B2 | Composition for treating prostate cancer (PCa) | CureVac SE (DE) | 2024-07-30 | — | — | US | disclosed |
| CN-110945022-B | Plasmodium sporozoite NPDP peptides as vaccine and novel malaria vaccine and antibody binding targets | 生物医学研究所 | 2024-04-05 | — | — | CN | disclosed |
| EP-3600398-B1 | HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023161526-A1 | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN | TRIDEM BIOSCIENCE GMBH & CO KG (AT) | 2023-08-31 | — | — | WO | disclosed |
| CN-108633278-B | Amyloid conjugates and uses and methods thereof | 艾拉科隆生物技术公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022161598-A1 | ANTIBODIES BROADLY TARGETING CORONAVIRUSES AND USES THEREOF | ETH ZURICH (CH) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022162012-A2 | ANTIBODIES BROADLY TARGETING CORONAVIRUSES AND USES THEREOF | ETH ZURICH (CH) | 2022-08-04 | — | — | WO | disclosed |
| EP-4031174-A1 | HUMAN ANTI-PD-L1 PEPTIDE VACCINES AND METHODS OF THEIR USE | Ohio State Innovation Foundation (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220184178-A1 | AMYLOID CONJUGATE AND USES AND METHODS THEREOF | ARACLON BIOTECH SL (ES) | 2022-06-16 | — | — | US | disclosed |
| CN-114630676-A | Human anti-PD-L1 peptide vaccines and methods of use thereof | 俄亥俄州创新基金会 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186595-A1 | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN | CD4, CD74, CD47 | NOD2 242/4885SIRT5 3490/4885PTPN1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.